All News & Research Articles
BrightFocus Foundation, an international nonprofit funder of Alzheimer’s, macular degeneration, and glaucoma research, presented its named vision awards for 2022 yesterday to leading vision researchers at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
BrightFocus-funded researchers—assisted by a citizen science video game-- were among the first to show that Alzheimer’s contributes to stalls in the brain’s tiniest blood vessels, and they’re working on possible treatments.
Global Nonprofit’s Science Support Leads to Breakthroughs
Scientists have discovered that a rare version of the so-called “neutral” APOE3 genotype, one they’ve named APOE3-Jacksonville (APOE3-Jac), may help protect against Alzheimer’s through increased lipid binding and cholesterol removal.
Years ago, a BrightFocus grantee said it might be possible to manipulate the blood-brain-barrier to treat Alzheimer’s disease. Now his hypothesis is driving an international effort to develop drugs for this purpose.
New evidence shows the same molecular pathway contributes to inflammation in AMD and lupus, helping to drive a hyperactive immune response in both diseases. The discovery could fast-track development and approval of existing anti inflammatory drugs to treat AMD.
Why does the impact of an Alzheimer’s risk factor vary by race and genetic ancestry? Researchers are learning the answers.
Preparing ahead of time can help you best manage your vision health. Here are some questions you can take along when you visit the doctor.
BrightFocus-funded researchers were among the first to “map” the normal 3D structure of a protein called myocilin, which is abundant in the drainage pathway of the eye. Now, with a second grant, they’ve designed antibodies to help diagnose and treat myocilin misfolding as it contributes to glaucoma.